Brokerages Set Inventiva S.A. Sponsored ADR (NASDAQ:IVA) PT at $16.00

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have received a consensus recommendation of “Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $16.2222.

IVA has been the subject of a number of recent analyst reports. Barclays assumed coverage on Inventiva in a report on Tuesday. They set an “overweight” rating and a $18.00 price target for the company. Leerink Partners began coverage on Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 target price for the company. Wolfe Research raised Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim lowered their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th.

Hedge Funds Weigh In On Inventiva

Several hedge funds have recently made changes to their positions in the company. Creative Planning purchased a new stake in shares of Inventiva in the 2nd quarter valued at about $32,000. Wealth Enhancement Advisory Services LLC increased its position in Inventiva by 54.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after buying an additional 5,843 shares during the period. NewEdge Advisors LLC purchased a new stake in Inventiva in the third quarter valued at approximately $116,000. Millennium Management LLC acquired a new stake in shares of Inventiva in the third quarter valued at approximately $649,000. Finally, UBS Group AG boosted its holdings in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after acquiring an additional 2,634,580 shares during the period. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

Shares of IVA opened at $6.16 on Friday. The firm’s fifty day simple moving average is $5.05 and its 200-day simple moving average is $4.80. Inventiva has a twelve month low of $2.23 and a twelve month high of $7.98.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.